Hair Relaxer / Uterine Cancer

● CAMPAIGN OPEN DISCOVERY / BELLWETHER SELECTION 2 signals
Uterine Cancer / Uterine Fibroids  ·  Chemical Hair Relaxers
DEFENDANT
L’Oréal / Revlon / SoftSheen-Carson
MDL / DOCKET
MDL 3060
N.D. Illinois
JUDGE
Hon. Mary Rowland
PLAINTIFFS
8,000+
BELLWETHER / TRIAL
Est. 2025
SETTLEMENT STATUS
None — active
📋 Case Overview

Chemical hair relaxers used predominantly by Black women contain endocrine-disrupting chemicals (EDCs) including parabens, bisphenol-A, formaldehyde, and phthalates. A 2022 NIH Sister Study found that frequent use of chemical hair relaxers was associated with significantly elevated uterine cancer risk. MDL 3060 is in active discovery with bellwether selection underway.

⚗ CAUSATION SUMMARY

The 2022 Chang et al. NIH study (JNCI) found a 2.55x increased risk of uterine cancer in frequent hair relaxer users — the key causation anchor. Endocrine-disrupting chemicals in relaxers mimic estrogen and disrupt hormonal pathways. Black women are disproportionately affected due to higher use rates and earlier age of first exposure.

⚖️ Litigation Status GROWING
MDL / Court
MDL 3060 — N.D. Illinois (Judge Mary Rowland)
Active Plaintiffs
8,000+

MDL formed in 2023. Discovery ongoing. Primary injury is uterine cancer and uterine fibroids. L'Oreal and Revlon are primary defendants. Bellwether selection projected 2025. Predominantly affects Black women who used chemical relaxers for years.

Key Verdicts & Settlements
⚖️
No verdicts yet — MDL in discovery
Bellwether selection underway. First trials projected late 2025 or 2026.
🔬
NIH Sister Study — 2.05x uterine cancer risk (2022)
Landmark NIH study of 33,000 women established causation link. Core science of the MDL.
📈
Filing trend: Growing. Campaign fully open. Strong NIH science, underserved plaintiff population, and no verdicts yet keeping CPL low. Best campaign window before bellwether outcomes.
📍 Geographic Exposure
Nationwide; African American communities disproportionately represented
Highest plaintiff concentrations: Southeast, Midwest, Northeast urban areas
No geographic restriction — product sold nationally
🏢 Key Defendants
DEFENDANT
ROLE
INTEL NOTE
L’Oréal USA
Primary manufacturer (Dark & Lovely, Mizani)
Largest defendant by market share
Revlon
Manufacturer (Creme of Nature, Realistic)
Bankruptcy complicates recovery; still named defendant
SoftSheen-Carson (L’Oréal subsidiary)
Manufacturer (Optimum, Dark & Lovely)
Co-defendant with L’Oréal
Strength of Nature (Godrej)
Manufacturer (Just For Me, Africa’s Best)
Growing number of claims
✅ Campaign Eligibility Criteria
Regular use of chemical hair relaxers for 4+ years
First use preferably before age 18 (early exposure strengthens case)
Diagnosed with uterine cancer (leiomyosarcoma or endometrial cancer) or uterine fibroids requiring surgery
Black/African American women have strongest case profile given exposure patterns
These criteria reflect general case strength indicators and are not legal advice. Contact CloudIntake to screen individual claimants.
📅 Litigation Timeline
2022
NIH Sister Study (Chang et al.) published in JNCI: 2.55x uterine cancer risk in frequent users
2022
First lawsuits filed; MDL petition submitted
2023
MDL 3060 formed in N.D. Illinois before Judge Rowland
2024
Discovery ongoing; bellwether pool selection underway
2025
Bellwether trial anticipated; causation experts disclosed
Hair Relaxer / Uterine Cancer — Intelligence Feed LIVE
📰 NEWS
Hair Relaxer Lawsuit Settlement | March 2026 Litigation Update
Mar 13, 2026 Lawsuit Information Center Read Source →
📰 NEWS
Court ruling allows Georgia woman to pursue lawsuit against makers of hair relaxer products
Mar 13, 2026 Georgia Recorder Read Source →
Feed All Torts
MASS TORT AD AGENCY
Saturated market. Unsaturated audiences.
Every firm is fishing the same pond for Hair Relaxer / Uterine Cancer leads. MTAA targets underserved audiences and demographics your competitors ignore.
See the Strategy →
Plaintiff attorneys only · mtaa.ai
JACOB SCORE™
Hair Relaxer / Uterine Cancer
52 / 100
ScienceModerate
MomentumDeveloping
CampaignModerate
TimelineDeveloping
VerdictsWeak
CAMPAIGN OPEN · NO VERDICTS YET
Jacob Score™ — Methodology & Legal Disclaimers
The Jacob Score is a composite 1–100 litigation opportunity index for mass torts, produced by the TortIntel editorial team at Mass Tort Ad Agency. It is updated periodically as litigation conditions change.

Score Dimensions (each rated 1–5)

Science — Peer-reviewed study quality and quantity, relative risk magnitude, replication across independent research groups, FDA or regulatory action taken, and estimated Daubert survivability based on published expert testimony and prior rulings.

Momentum — MDL formation and phase, plaintiff count trajectory, case consolidation activity, and overall litigation velocity.

Campaign — Current filing window status, case saturation, defendant solvency, estimated qualifying population size, and co-defendant dynamics.

Timeline — Proximity to first expected resolution or bellwether trial, current discovery or Daubert phase, and estimated time-to-value for a signed plaintiff.

Verdicts — Confirmed plaintiff jury verdicts, bellwether trial win/loss record, and size or certainty of any established settlement fund. 1 = pre-trial · 2 = mixed early results · 3 = partial settlements or initial wins · 4 = confirmed large verdicts or funded settlement · 5 = landmark verdicts with formal settlement program.

LEGAL DISCLAIMERS

The Jacob Score and all associated content on TortIntel.ai is provided solely for mass tort business intelligence and law firm marketing decision-making purposes. It does not constitute legal advice, litigation strategy advice, or a recommendation to file or refrain from filing any lawsuit.

The Jacob Score is an editorial opinion based on publicly available data including court filings, published scientific literature, regulatory actions, and reported settlement information. It is not a guarantee of future litigation outcomes. Past verdicts and settlements are not predictive of future results in any specific case.

TortIntel.ai and Mass Tort Ad Agency make no representation that any score is complete, accurate, or current. Litigation conditions change rapidly. Attorneys must conduct independent due diligence and consult qualified co-counsel before making any case acquisition or litigation funding decisions based on this or any other intelligence tool.

This score must not be used to evaluate, accept, or reject any individual plaintiff’s case. Case-specific merit depends on individual facts, applicable state law, expert medical and scientific analysis, and jurisdiction-specific statutes of limitations — all of which are beyond the scope of this tool.

No attorney-client relationship is created by use of this platform. TortIntel.ai is not a law firm and does not provide legal services. © 2026 Mass Tort Ad Agency / TortIntel.ai. All rights reserved.
DATA ACCURACY
See something incorrect? Reach out and we'll fix it.
🔔 Alert Me
Get notified when Hair Relaxer / Uterine Cancer updates.
✓ You're subscribed. We'll notify you of key developments.
TORTINTEL PRO
Abuse Discovery Tracker
Emerging institutional abuse cases — church, scouting, youth programs. Real-time defendant monitoring, filing window alerts, and filing cluster detection.
View Pro Features →